Anne-Marie Koop

9 321 72. Lauva IK, Brody E, Tiger E, Kent RL, Copper G 4th, Marino TA. Control of myocardial tissue components and cardiocyte organelles in pressure-overload hypertrophy of the cat right ventricle. Am J Anat United States; 1986;177:71–80. 73. Olivetti G, Ricci R, Lagrasta C, Maniga E, Sonnenblick EH, Anversa P. Cellular basis of wall remodeling in long-term pressure overload-induced right ventricular hypertrophy in rats. Circ Res Department of Pathology, University of Parma, 43100 Parma; 1988; 63 :648–657. 74. Sack MN, Disch DL, Rockman HA, Kelly DP. A role for Sp and nuclear receptor transcription factors in a cardiac hypertrophic growth program. Proc Natl Acad Sci U S A D.P. Kelly, Center for Cardiovascular Research, Box 8086, Washington Univ. Sch. of Medicine, St. Louis, MO 63110, United States; 1997;94:6438–6443. 75. Sheikh AM, Barrett C, Villamizar N, Alzate O, Valente AM, Herlong JR, Craig D, Lodge A, Lawson J, Milano C, Jaggers J. Right ventricular hypertrophy with early dysfunction: A proteomics study in a neonatal model. J Thorac Cardiovasc Surg A.M. Sheikh, Department of Pediatric Cardiac Surgery, the Neuroproteomics Center, Durham, NC, United States; 2009;137:1146–1153. 76. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297:L1013-32. 77. Chow SL, Maisel AS, Anand I, Bozkurt B, Boer RA De, Felker GM, Fonarow GC, Greenberg B, Januzzi JL, Kiernan MS, Liu PP, Wang TJ, Yancy CW, Zile MR. Role of biomarkers for the prevention, assessment, and management of heart failure: A scientific statement from the American Heart Association. Circulation. 2017. 78. Liu CH, Abrams ND, Carrick DM, Chander P, Dwyer J, Hamlet MRJ, Macchiarini F, Prabhudas M, Shen GL, Tandon P, Vedamony MM. Biomarkers of chronic inflammation in disease development and prevention: Challenges and opportunities. Nat Immunol Nature Publishing Group; 2017;18:1175–1180. 79. deSouza NM, Achten E, Alberich-Bayarri A, Bamberg F, Boellaard R, Clément O, Fournier L, Gallagher F, Golay X, Heussel CP, Jackson EF, Manniesing R, Mayerhofer ME, Neri E, O’Connor J, Oguz KK, Persson A, Smits M, Beek EJR van, Zech CJ. Validated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL* subcommittee of the European Society of Radiology (ESR). Insights Imaging Insights into Imaging; 2019;10. 80. Daniels LB, Maisel AS. Natriuretic Peptides. J Am Coll Cardiol 2007;50:2357–2368. 81. Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003;108:833–838. 82. Hudson MP, O’Connor CM, Gattis WA, Tasissa G, Hasselblad V, Holleman CM, Gaulden LH, Sedor F, Ohman EM. Implications of elevated cardiac troponin t in ambulatory patients with heart failure: A prospective analysis. Am Heart J 2004;147:546–552. 83. Vecchia L La, Mezzena G, Zanolla L, Paccanaro M, Varotto L, Bonanno C, Ometto R. Cardiac Troponin I as diagnostic and prognostic marker in severe heart failure. J Hear Lung Transplant 2000;19:644–652.